Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Conditions:  Diffuse Large B-Cell Lymphoma;  Diffuse Large B-Cell Lymphoma Activated B-Cell Type;  Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;  Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;  High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;  High G rade B-Cell Lymphoma, Not Otherwise Specified;  T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Interventions:  Drug: Cyclophosphamide;  Drug: Doxorubicin Hydrochloride;  Drug: Prednisone;  Biological: Rituximab;  Drug: Spleen Tyrosine Kinase Inhibitor TAK-659;  Drug: Vincristine Sulfate Sponsors:  Northwestern University;  National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials